乌帕替尼在溃疡性结肠炎和克罗恩病中有效且安全:前瞻性真实世界经验
本研究前瞻性分析了乌帕替尼治疗溃疡性结肠炎(UC)和克罗恩病(CD)的真实世界疗效与安全性,共105例患者随访8周,其中84例因活动性肠腔或肛周病变纳入分析。结果显示UC和CD患者均有快速临床应答和缓解,且安全性可接受。
要点
- UC患者第4周临床应答19/25(76.0%),第8周23/27(85.2%)。
- CD患者第8周临床应答13/17(76.5%),临床缓解12/17(70.6%)。
- 痤疮是最常见不良事件,105例中24例(22.9%)发生。
核心结论
- 在 medically resistant 的UC或CD患者中,乌帕替尼快速有效且安全,包括既往托法替布暴露者。
研究设计与样本
- 前瞻性分析,采用本机构正式治疗方案,在0、2、4、8周预定时间点评估临床结局。
- 共105例患者接受乌帕替尼并随访8周,其中84例(44例UC,40例CD)因活动性肠腔或肛周病变起始治疗并纳入分析。
主要发现
- UC患者第4周临床应答19/25(76.0%),第8周23/27(85.2%);第4周临床缓解18/26(69.2%),第8周22/27(81.5%)。
- 既往托法替布暴露者中,9例中有7例(77.8%)在第8周达到临床缓解。
- CD患者第8周临床应答13/17(76.5%),临床缓解12/17(70.6%)。
- 粪钙卫蛋白和C反应蛋白升高的患者中,分别有62%和64%在第8周恢复正常。
- UC和CD患者早在第2周即观察到临床缓解,缓解率分别为36%和56.3%。
关键数值与推荐
- 100%患者既往接受过抗肿瘤坏死因子治疗,89.3%接受过2种或以上先进治疗。
- 痤疮为最常见不良事件,105例中24例(22.9%)发生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Upadacitinib is a novel selective Janus kinase 1 inhibitor that has shown efficacy in the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD), and has received Food and Drug Administration approval for UC. We report a large real-world experience with upadacitinib in UC and CD. METHODS: We performed a prospective analysis of clinical outcomes on upadacitinib in patients with UC and CD using predetermined intervals at weeks 0, 2, 4, and 8 as part of a formalized treatment protocol at our institution. We used the Simple Clinical Colitis Activity Index and the Harvey-Bradshaw index, as well as C-reactive protein and fecal calprotectin to assess efficacy, and also recorded treatment-related adverse events and serious adverse events. RESULTS: A total of 105 patients were followed up for 8 weeks on upadacitinib, 84 of whom (44 UC patients, 40 CD patients) were initiated because of active luminal or perianal disease and included in the analysis. One hundred percent previously received anti-tumor necrosis factor therapy, and 89.3% had received 2 or more advanced therapies. At 4 and 8 weeks of treatment for UC, 19 of 25 (76.0%) and 23 of 27 (85.2%) achieved clinical response and 18 of 26 (69.2%) and 22 of 27 (81.5%) achieved clinical remission, respectively. Of those who previously were tofacitinib-exposed, 7 of 9 (77.8%) achieved clinical remission by 8 weeks. In CD, 13 of 17 (76.5.%) achieved clinical response and 12 of 17 (70.6%) achieved clinical remission by 8 weeks. Of those with increased fecal calprotectin and C-reactive protein levels, 62% and 64% normalized by week 8, respectively. Results were seen as early as week 2 in both UC and CD, with clinical remission rates of 36% and 56.3.%, respectively. Acne was the most commonly reported adverse event, occurring in 24 of 105 patients (22.9%). CONCLUSIONS: In this large real-world experience in medically resistant patients with UC or CD, we report that upadacitinib is rapidly effective and safe, including in those who had prior tofacitinib exposure. This study was approved by the Institutional Review Board at the University of Chicago (IRB20-1979).
引用
- Friedberg S, Choi D, Hunold T, et al. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023. PMID: 36898598. doi:10.1016/j.cgh.2023.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。